Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E, Garvin J, Bradley MB, Bhatia M, Satwani P, George D, Del Toro G, Hawks R, Wolownik K, Foley S, Cheung YK, Schwartz J, van de Ven C, Baxter-Lowe LA, Cairo MS. Waxman IM, et al. Among authors: bradley mb. Pediatr Transplant. 2009 Jun;13(4):464-74. doi: 10.1111/j.1399-3046.2008.01000.x. Epub 2008 Sep 10. Pediatr Transplant. 2009. PMID: 18785912
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.
Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C, Satwani P, Bhatia M, Garvin JH, Bradley MB, Harrison L, Morris E, Della-Latta P, Schwartz J, Baxter-Lowe LA, Cairo MS. Geyer MB, et al. Among authors: bradley mb. Br J Haematol. 2011 Oct;155(2):218-34. doi: 10.1111/j.1365-2141.2011.08822.x. Epub 2011 Aug 16. Br J Haematol. 2011. PMID: 21848882 Free PMC article.
Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality.
George D, El-Mallawany NK, Jin Z, Geyer M, Della-Latta P, Satwani P, Garvin JH, Bradley MB, Bhatia M, van de Ven C, Morris E, Schwartz J, Cairo MS. George D, et al. Among authors: bradley mb. Br J Haematol. 2012 Jan;156(1):99-108. doi: 10.1111/j.1365-2141.2010.08468.x. Epub 2011 Oct 18. Br J Haematol. 2012. PMID: 22008222 Free article.
Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.
Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, George D, Bradley MB, Harrison L, Petrillo K, Schwartz J, Foley S, Hawks R, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Among authors: bradley mb. Biol Blood Marrow Transplant. 2013 Apr;19(4):552-61. doi: 10.1016/j.bbmt.2012.12.005. Epub 2012 Dec 16. Biol Blood Marrow Transplant. 2013. PMID: 23253557 Free article.
Outcomes of unrelated cord blood transplantation in pediatric recipients.
Styczynski J, Cheung YK, Garvin J, Savage DG, Billote GB, Harrison L, Skerrett D, Wolownik K, Wischhover C, Hawks R, Bradley MB, Del Toro G, George D, Yamashiro D, van de Ven C, Cairo MS. Styczynski J, et al. Among authors: bradley mb. Bone Marrow Transplant. 2004 Jul;34(2):129-36. doi: 10.1038/sj.bmt.1704537. Bone Marrow Transplant. 2004. PMID: 15107815 Clinical Trial.
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.
Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, Baxter-Lowe LA, Schwartz J, Qualter E, Hawks R, Wolownik K, Foley S, Militano O, Leclere J, Cheung YK, Cairo MS. Bradley MB, et al. Bone Marrow Transplant. 2007 Oct;40(7):621-31. doi: 10.1038/sj.bmt.1705785. Epub 2007 Jul 30. Bone Marrow Transplant. 2007. PMID: 17660841
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS. Styczynski J, et al. Among authors: bradley mb. Bone Marrow Transplant. 2011 Jun;46(6):790-9. doi: 10.1038/bmt.2010.209. Epub 2010 Sep 6. Bone Marrow Transplant. 2011. PMID: 20818441 Clinical Trial.
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS. Le Gall JB, et al. Among authors: bradley mb. Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11. Bone Marrow Transplant. 2013. PMID: 22684047 Clinical Trial.
26 results